A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy
ID Number 14-1292Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
You have been diagnosed with ovarian cancer, primary peritoneal cancer (the lining of the abdomen) or fallopian tube cancer. To participate in this study you will be tested for a specific type of genetic mutation in the BRCA genes. A mutation is a change in your deoxyribonucleic acid (DNA) which affects how some processes in the body work. You had an improvement in your cancer (response) following first line platinum based chemotherapy. This study is being carried out to see if a new treatment being tested, called olaparib, is effective in treating your ovarian cancer and preventing it from coming back as quickly as it could otherwise do without any medication. The current medical practice in your situation is not to take further medications until the cancer comes back.
Recruiting Patients: Yes